Low-Dose Naltrexone for Pruritus in Systemic Sclerosis

Table 1

Clinical features of systemic sclerosis participants.

Patient	Disease onset*, subtype	Pre-LDN pruritus	Post-LDN pruritus	Pre-LDN mRSS	Post-LDN mRSS	Pre-LDN UCLA SCTC GIT 2.0	Post-LDN UCLA SCTC GIT 2.0
1	2 years, diffuse	10	4	28	24	Total: 0.355; (i) Reflux: 0.63; (ii) Distention: 0.5; (iii) Soilage: 0; (iv) Diarrhea: 0; (v) Constipation: 1.25; (vi) Social: 0; (vii) Emotional: 0.11	Total: 0.302; (i) Reflux: 0.5; (ii) Distention: 0.5; (iii) Soilage: 0; (iv) Diarrhea: 0; (v) Constipation: 1; (vi) Social: 0; (vii) Emotional: 0.11
2	11 years, diffuse	6	0	19	17	Total: 0.395; (i) Reflux: 0.63; (ii) Distention: 1.75; (iii) Soilage: 0; (iv) Diarrhea: 0.5; (v) Constipation: 0.5; (vi) Social: 0.17; (vii) Emotional 0.22	Total: 0.216; (i) Reflux: 0.38; (ii) Distention: 0.5; (iii) Soilage: 0; (iv) Diarrhea: 0; (v) Constipation: 0.25; (vi) Social: 0.17; (vii) Emotional 0.22
3	1 year, limited	8	0	12	12	Total: 0.54; (i) Reflux: 0.25; (ii) Distention: 1.5; (iii) Soilage: 0; (iv) Diarrhea: 0; (v) Constipation: 1.25; (vi) Social: 0.33; (vii) Emotional 0.44	Total: 0.216; (i) Reflux: 0.13; (ii) Distention: 0.5; (iii) Soilage: 0; (iv) Diarrhea: 0; (v) Constipation: 0.5; (vi) Social: 0.17; (vii) Emotional 0.22

*First non-Raynaud’s phenomenon symptom; LDN: low-dose naltrexone; mRSS: modified Rodnan skin score; UCLA SCTC GIT 2.0: University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0.